Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia (CHEMCHA)
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)
Sponsor: Global Health Uganda LTD
Listed as NCT04844099, this PHASE3 trial focuses on Malaria and Sickle Cell Anemia in Children and remains completed. Sponsored by Global Health Uganda LTD, it has been updated 6 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting · Phase: PHASE2_PHASE3 → PHASE3
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Global Health Uganda LTD
- Indiana University
- Liverpool School of Tropical Medicine
- Makerere University
- University of Bergen
- University of Malawi
For direct contact, visit the study record on ClinicalTrials.gov .